Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2017, Article ID 3813540, 8 pages
https://doi.org/10.1155/2017/3813540
Review Article

Antithyroid Drug Therapy for Graves’ Disease and Implications for Recurrence

Department of Endocrinology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China

Correspondence should be addressed to Guang Wang; moc.621@8866gwrd

Received 18 December 2016; Revised 29 March 2017; Accepted 2 April 2017; Published 26 April 2017

Academic Editor: Jack Wall

Copyright © 2017 Jia Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. De Leo, S. Y. Lee, and L. E. Braverman, “Hyperthyroidism,” Lancet, vol. 388, no. 10047, pp. 906–918, 2016. View at Publisher · View at Google Scholar · View at Scopus
  2. V. Sundaresh, J. P. Brito, Z. Wang et al., “Comparative effectiveness of therapies for Graves’ hyperthyroidism: a systematic review and network meta-analysis,” The Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 9, pp. 3671–3677, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Ma, J. Xie, H. Wang, J. Li, and S. Chen, “Radioiodine therapy versus antithyroid medications for Graves’ disease,” Cochrane Database of Systematic Reviews, vol. 2, article CD010094, 2016. View at Publisher · View at Google Scholar
  4. D. S. Cooper, “Antithyroid drugs,” The New England Journal of Medicine, vol. 352, no. 9, pp. 905–917, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. X. G. Vos, E. Endert, A. H. Zwinderman, J. G. Tijssen, and W. M. Wiersinga, “Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves’ hyperthyroidism,” The Journal of Clinical Endocrinology and Metabolism, vol. 101, no. 4, pp. 1381–1389, 2016. View at Publisher · View at Google Scholar
  6. K. W. Kim, Y. J. Park, T. Y. Kim, D. J. Park, K. S. Park, and B. Y. Cho, “Susceptible alleles of the CD40 and CTLA-4 genes are not associated with the relapse after antithyroid withdrawal in Graves’ disease,” Thyroid, vol. 17, no. 12, pp. 1229–1234, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. H. Allannic, R. Fauchet, J. Orgiazzi et al., “Antithyroid drugs and Graves’ disease: a prospective randomized evaluation of the efficacy of treatment duration,” Journal of Clinical Endocrinology and Metabolism, vol. 70, no. 3, pp. 675–679, 1990. View at Publisher · View at Google Scholar
  8. L. Liu, H. Lu, Y. Liu, C. Liu, and C. Xun, “Predicting relapse of Graves’ disease following treatment with antithyroid drugs,” Experimental and Therapeutic Medicine, vol. 11, no. 4, pp. 1443–1458, 2016. View at Google Scholar
  9. R. V. Garcia-Mayor, C. Paramo, R. Luna Cano, L. F. Pérez Mendez, J. C. Galofré, and A. Andrade, “Antithyroid drug and Graves’ hyperthyroidism. Significance of treatment duration and TRAb determination on lasting remission,” Journal of Endocrinological Investigation, vol. 15, no. 11, pp. 815–820, 1992. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Duprey, M. F. Louis, B. Ducornet et al., “Improvement of the prognosis of Basedow’s disease by using high doses of carbimazole,” Presse médicale (Paris, France: 1983), vol. 17, no. 22, pp. 1124–1127, 1988. View at Google Scholar
  11. A. P. Weetman, S. Ratanachaiyavong, and G. W. Middleton, “Prediction of outcome in Graves’ disease after carbimazole treatment,” Quarterly Journal of Medicine, vol. 59, no. 228, pp. 409–419, 1986. View at Google Scholar
  12. H. Nakamura, J. Y. Noh, K. Itoh, S. Fukata, A. Miyauchi, and N. Hamada, “Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by graves’ disease,” The Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 6, pp. 2157–2162, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. C. T. He, A. T. Hsieh, D. Pei et al., “Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves’ hyperthyroidism,” Clinical Endocrinology, vol. 60, no. 6, pp. 676–681, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. M. C. Peixoto, A. Buescu, M. R. B. Gonçalves, M. de Souza Albernaz, C. M. Coeli, and M. Vaisman, “Antithyroid drugs for the treatment of Graves disease: a randomized clinical trial,” Endocrinologist, vol. 16, no. 6, pp. 344–348, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. D. S. Ross, H. B. Burch, D. S. Cooper et al., “2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis,” Thyroid, vol. 26, no. 10, pp. 1343–1421, 2016. View at Publisher · View at Google Scholar
  16. P. Abraham, A. Avenell, S. C. McGeoch, L. F. Clark, and J. S. Bevan, “Antithyroid drug regimen for treating Graves’ hyperthyroidism,” Cochrane Database of Systematic Reviews, vol. 20, no. 1, p. CD003420, 2010. View at Publisher · View at Google Scholar
  17. P. A. Dahlberg, F. A. Karlsson, B. Lindstrom, and L. Wide, “Studies of thyroid hormone and methimazole levels in patients with Graves’ disease on a standardized anti-thyroid drug regimen,” Clinical Endocrinology, vol. 14, no. 6, pp. 555–562, 1981. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Liu, Y. Duan, and X. Wu, “Prospective study on the relationship between treatment duration of antithyroid drug and remission rate of Graves’ disease,” Zhonghua Yi Xue Za Zhi, vol. 80, no. 11, pp. 835–837, 2000. View at Google Scholar
  19. F. Morales García, A. Cayuela, N. García Hernández et al., “Long-term maintenance of low-dose antithyroid drugs versus drug withdrawal in patients with Graves’ hyperthyroidism,” Endocrinologia y Nutricion, vol. 55, no. 3, pp. 123–131, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. E. Mazza, M. Carlini, D. Flecchia et al., “Long-term follow-up of patients with hyperthyroidism due to Graves’ disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: a retrospective study,” Journal of Endocrinological Investigation, vol. 31, no. 10, pp. 866–872, 2008. View at Publisher · View at Google Scholar
  21. D. Glinoer, P. De Nayer, and M. Bex, “Effects of L-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves’ hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study,” European Journal of Endocrinology, vol. 144, no. 5, pp. 475–483, 2001. View at Publisher · View at Google Scholar
  22. R. Hoermann, B. Quadbeck, U. Roggenbuck et al., “Relapse of Graves’ disease after successful outcome of antithyroid drug therapy: results of a prospective randomized study on the use of levothyroxine,” Thyroid, vol. 12, no. 12, pp. 1119–1128, 2002. View at Publisher · View at Google Scholar
  23. G. Mastorakos, A. G. Doufas, E. Mantzos, J. Mantzos, and D. A. Koutras, “T4 but not T3 administration is associated with increased recurrence of Graves’ disease after successful medical therapy,” Journal of Endocrinological Investigation, vol. 26, no. 10, pp. 979–984, 2003. View at Publisher · View at Google Scholar
  24. A. Antonelli, S. M. Ferrari, A. Corrado, A. Di Domenicantonio, and P. Fallahi, “Autoimmune thyroid disorders,” Autoimmunity Reviews, vol. 14, no. 2, pp. 174–180, 2015. View at Publisher · View at Google Scholar · View at Scopus
  25. G. Obiols Alfonso, J. Mesa Manteca, R. Simo Canonge, L. García Pascual, C. García Alonso, and J. M. Tresánchez Trías, “Effect of carbimazole and dexamethasone on the TSH bond (TBII) inhibiting immunoglobulins in Graves-Basedow disease,” Revista Clínica Española, vol. 183, no. 8, pp. 401–404, 1988. View at Google Scholar
  26. L. Chen, H. Q. Wang, Y. Y. Gao et al., “Comparison of methimazole/hydrocortisone ointment with oral methimazole in patients with Graves disease: a prospective, randomized, open-label, parallel-group, 18-month study,” Current Therapeutic Research, Clinical and Experimental, vol. 69, no. 4, pp. 305–317, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Kubota, H. Ohye, E. Nishihara et al., “Effect of high dose methylprednisolone pulse therapy followed by oral prednisolone administration on the production of anti-TSH receptor antibodies and clinical outcome in Graves’ disease,” Endocrine Journal, vol. 52, no. 6, pp. 735–741, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. D. El Fassi, C. H. Nielsen, S. J. Bonnema, H. C. Hasselbalch, and L. Hegedus, “B lymphocyte depletion with the monoclonal antibody rituximab in Graves’ disease: a controlled pilot study,” The Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 5, pp. 1769–1772, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. B. Huszno, M. Trofimiuk, F. Golkowski, T. Plinta, and Z. Szybinski, “Assessment of early immunosuppressive therapy in the prevention of complications of Graves’ disease,” Przeglad Lekarski, vol. 61, no. 8, pp. 868–871, 2004. View at Google Scholar
  30. T. Struja, L. Guebelin, A. Kutz, H. Fehlberg, B. Mueller, and P. Schuetz, “Does immunosuppressive therapy improve outcomes in Graves’ disease? A systematic review and meta-analysis,” Thyroid, vol. 26, no. 5, pp. 634–640, 2016. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Carle, I. B. Pedersen, N. Knudsen et al., “Epidemiology of subtypes of hyperthyroidism in Denmark: a population-based study,” European Journal of Endocrinology, vol. 164, no. 5, pp. 801–809, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Kourime, S. McGowan, M. Al-Towati et al., “Outcome of thyrotoxicosis in childhood and adolescence in a geographically define area; a 24-year experience,” in Hormone Research in Paediatrics, M. Kourime, Ed., vol. 84, pp. 551–552, Abderrahim Harouchi Hôpital, Casablanca, Morocco, 2015. View at Publisher · View at Google Scholar
  33. T. Yamada, T. Aizawa, Y. Koizumi, I. Komiya, K. Ichikawa, and K. Hashizume, “Age-related therapeutic response to antithyroid drug in patients with hyperthyroid Graves’ disease,” Journal of the American Geriatrics Society, vol. 42, no. 5, pp. 513–516, 1994. View at Publisher · View at Google Scholar
  34. A. Allahabadia, J. Daykin, R. L. Holder, M. C. Sheppard, S. C. Gough, and J. A. Franklyn, “Age and gender predict the outcome of treatment for Graves’ hyperthyroidism,” The Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 3, pp. 1038–1042, 2000. View at Publisher · View at Google Scholar
  35. M. L. Tanda, E. Piantanida, L. Liparulo et al., “Prevalence and natural history of Graves’ orbitopathy in a large series of patients with newly diagnosed Graves’ hyperthyroidism seen at a single center,” The Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 4, pp. 1443–1449, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. J. A. Da Silva, “Sex hormones, glucocorticoids and autoimmunity: facts and hypotheses,” Annals of the Rheumatic Diseases, vol. 54, no. 1, pp. 6–16, 1995. View at Google Scholar
  37. L. O. Chailurkit, W. Aekplakorn, and B. Ongphiphadhanakul, “The relationship between circulating estradiol and thyroid autoimmunity in males,” European Journal of Endocrinology, vol. 170, no. 1, pp. 63–67, 2014. View at Google Scholar
  38. P. Anagnostis, F. Adamidou, S. A. Polyzos et al., “Predictors of long-term remission in patients with Graves’ disease: a single center experience,” Endocrine, vol. 44, no. 2, pp. 448–453, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. F. Magri, F. Zerbini, M. Gaiti et al., “Gender influences the clinical presentation and long-term outcome of Graves’ disease,” Endocrine Practice, vol. 22, no. 11, pp. 1336–1342, 2016. View at Publisher · View at Google Scholar
  40. E. Mohlin, H. Filipsson Nystrom, and M. Eliasson, “Long-term prognosis after medical treatment of Graves’ disease in a northern Swedish population 2000-2010,” European Journal of Endocrinology, vol. 170, no. 3, pp. 419–427, 2014. View at Publisher · View at Google Scholar · View at Scopus
  41. P. W. Wang, I. Y. Chen, S. H. Juo, E. Hsi, R. T. Liu, and C. J. Hsieh, “Genotype and phenotype predictors of relapse of Graves’ disease after antithyroid drug withdrawal,” European Thyroid Journal, vol. 1, no. 4, pp. 251–258, 2013. View at Publisher · View at Google Scholar
  42. J. Y. Hsiao, M. C. Hsieh, K. J. Tien, S. C. Hsu, S. J. Shin, and S. R. Lin, “Association between a C/T polymorphism in exon 33 of the thyroglobulin gene is associated with relapse of Graves’ hyperthyroidism after antithyroid withdrawal in Taiwanese,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 8, pp. 3197–3201, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. D. Glinoer, “Clinical epidemiology of Graves’ disease: a multicentric prospective study in Belgium,” Revue Médicale de Bruxelles, vol. 21, no. 4, pp. 296–299, 2000. View at Google Scholar
  44. B. Quadbeck, U. Roggenbuck, O. E. Janssen et al., “Impact of smoking on the course of Graves’ disease after withdrawal of antithyroid drugs,” Experimental and Clinical Endocrinology and Diabetes, vol. 114, no. 8, pp. 406–411, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. Z. Gerenova and Y. Vulkov, “Clinical significance of serum T3/T4 ratio in the course of antithyroid drug therapy in Graves’ disease patients,” Bulletin Médical, vol. 8, no. 2, pp. 11–13, 2000. View at Google Scholar
  46. J. Gerenova, I. Tzvetanova, J. Valkov, and V. Tzoneva, “Changes in serum levels of free T3 and free T4 and ratio FT3/FT4 during treatment of Graves’ disease with methimazole,” Bulgarian Medicine, vol. 8, no. 6, pp. 9–11, 2000. View at Google Scholar
  47. C. M. Khanna, L. R. Shankar, C. B. Jaggi, J. K. Bansal, and P. Chugh, “Predictor of outcome of hyperthyroidism due to Graves’ disease: serum triiodothyronine/thyroxine ratio,” The Journal of the Association of Physicians of India, vol. 44, no. 2, pp. 98–101, 1996. View at Google Scholar
  48. J. L. Codaccioni, J. Orgiazzi, P. Blanc, M. Pugeat, R. Roulier, and P. Carayon, “Lasting remissions in patients treated for Graves’ hyperthyroidism with propranolol alone: a pattern of spontaneous evolution of the disease,” The Journal of Clinical Endocrinology and Metabolism, vol. 67, no. 4, pp. 656–662, 1988. View at Publisher · View at Google Scholar
  49. P. Laurberg, “Remission of Graves’ disease during anti-thyroid drug therapy. Time to reconsider the mechanism?” European Journal of Endocrinology, vol. 155, no. 6, pp. 783–786, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Matsumoto, J. Yoshimura Noh, K. Mukasa et al., “Predictors of recurrence of Graves’ disease after medical treatment,” Thyroid, vol. 23, no. S1, p. A101, 2013. View at Publisher · View at Google Scholar · View at Scopus
  51. S. Hwang, Y. Cho, D. Y. Shin, M. K. Song, and E. J. Lee, “High cut-off value of a chimeric TSH receptor (Mc4)-based bioassay may improve prediction of relapse in Graves’ disease for 12 months,” Endocrine, vol. 48, no. 1, pp. 89–95, 2015. View at Google Scholar
  52. G. Barbesino and Y. Tomer, “Clinical review: clinical utility of TSH receptor antibodies,” The Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 6, pp. 2247–2255, 2013. View at Publisher · View at Google Scholar · View at Scopus
  53. C. Giuliani, D. Cerrone, N. Harii et al., “A TSHR-LH/CGR chimera that measures functional thyroid-stimulating autoantibodies (TSAb) can predict remission or recurrence in Graves’ patients undergoing antithyroid drug (ATD) treatment,” The Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 7, pp. E1080–E1087, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. X. Liu, B. Shi, and H. Li, “Valuable predictive features of relapse of Graves’ disease after antithyroid drug treatment,” Annales d’endocrinologie, vol. 76, no. 6, pp. 679–683, 2015. View at Google Scholar
  55. H. Kwon, W. Kim, E. Jang et al., “Usefulness of thyroid stimulating antibody at the time of antithyroid drug withdrawal in predicting relapse of Graves’ hyperthyroidism,” Thyroid, vol. 25, no. S1, p. A11, 2015. View at Publisher · View at Google Scholar
  56. O. Eber and W. Langsteger, “Clinical aspects of autoimmune thyroid diseases,” Acta Medica Austriaca, vol. 21, no. 1, pp. 1–7, 1994. View at Google Scholar
  57. T. Sato, I. Takata, T. Taketani, K. Saida, and H. Nakajima, “Concurrence of Graves’ disease and Hashimoto’s thyroiditis,” Archives of Disease in Childhood, vol. 52, no. 12, pp. 951–955, 1977. View at Publisher · View at Google Scholar
  58. M. Stefanic and I. Karner, “Thyroid peroxidase autoantibodies are associated with a lesser likelihood of late reversion to hyperthyroidism after successful non-ablative treatment of Graves’ disease in Croatian patients,” Journal of Endocrinological Investigation, vol. 37, no. 1, pp. 71–77, 2014. View at Publisher · View at Google Scholar · View at Scopus
  59. P. Morosini, G. Arnaldi, A. Taccaliti et al., “Antithyroid antibody tests for hyperthyroidism. Analysis of 315 patients,” Recenti Progressi in Medicina, vol. 85, no. 11, pp. 521–525, 1994. View at Google Scholar
  60. P. Laurberg, B. Nygaard, S. Andersen et al., “Association between TSH-receptor autoimmunity, hyperthyroidism, goitre, and orbitopathy in 208 patients included in the remission induction and sustenance in Graves’ disease study,” Journal of Thyroid Research, vol. 2014, Article ID 165487, 6 pages, 2014. View at Google Scholar
  61. A. K. Eckstein, H. Lax, C. Losch et al., “Patients with severe Graves’ ophthalmopathy have a higher risk of relapsing hyperthyroidism and are unlikely to remain in remission,” Clinical Endocrinology, vol. 67, no. 4, pp. 607–612, 2007. View at Publisher · View at Google Scholar · View at Scopus
  62. D. Y. Chen, P. F. Schneider, X. S. Zhang, X. Y. Luo, Z. M. He, and T. H. Chen, “Changes in Graves’ ophthalmopathy after radioiodine and anti-thyroid drug treatment of Graves’ disease from 2 prospective, randomized, open-label, blinded end point studies,” Experimental and Clinical Endocrinology & Diabetes, vol. 122, no. 1, pp. 1–6, 2014. View at Publisher · View at Google Scholar · View at Scopus
  63. P. Laurberg, D. C. Berman, S. Andersen, and I. Bulow Pedersen, “Sustained control of Graves’ hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves’ orbitopathy,” Thyroid, vol. 21, no. 9, pp. 951–956, 2011. View at Publisher · View at Google Scholar · View at Scopus
  64. P. Laurberg, G. Wallin, L. Tallstedt, M. Abraham-Nordling, G. Lundell, and O. Tørring, “TSH-receptor autoimmunity in Graves’ disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study,” European Journal of Endocrinology, vol. 158, no. 1, pp. 69–75, 2008. View at Publisher · View at Google Scholar · View at Scopus
  65. A. Antonelli, S. M. Ferrari, A. Corrado, E. Ferrannini, and P. Fallahi, “Increase of interferon-gamma inducible CXCL9 and CXCL11 serum levels in patients with active Graves’ disease and modulation by methimazole therapy,” Thyroid, vol. 23, no. 11, pp. 1461–1469, 2013. View at Publisher · View at Google Scholar · View at Scopus
  66. L. Elbers, M. Mourits, and W. Wiersinga, “Outcome of very long-term treatment with antithyroid drugs in Graves’ hyperthyroidism associated with Graves’ orbitopathy,” Thyroid, vol. 21, no. 3, pp. 279–283, 2011. View at Publisher · View at Google Scholar · View at Scopus
  67. M. Marino, F. Latrofa, F. Menconi, L. Chiovato, and P. Vitti, “Role of genetic and non-genetic factors in the etiology of Graves’ disease,” Journal of Endocrinological Investigation, vol. 38, no. 3, pp. 283–294, 2015. View at Publisher · View at Google Scholar · View at Scopus
  68. P. W. Wang, I. Y. Chen, R. T. Liu, C. J. Hsieh, E. Hsi, and S. H. Juo, “Cytotoxic T lymphocyte-associated molecule-4 gene polymorphism and hyperthyroid Graves’ disease relapse after antithyroid drug withdrawal: a follow-up study,” The Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 7, pp. 2513–2518, 2007. View at Publisher · View at Google Scholar · View at Scopus
  69. D. Glowacka, C. Loesch, K. T. Johnson et al., “The T393C polymorphism of the Galphas gene (GNAS1) is associated with the course of Graves’ disease,” Hormone and Metabolic Research = Hormon- und Stoffwechselforschung = Hormones et métabolisme, vol. 41, no. 6, pp. 430–435, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. R. Vita, D. Lapa, F. Trimarchi, and S. Benvenga, “Certain HLA alleles are associated with Graves’ disease (GD) in patients in whom hyperthyroidism is preceded by stressful events (SE),” in Thyroid, R. Vita, D. Lapa, F. Trimarchi, and S. Benvenga, Eds., vol. 25, p. A205, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy, 2015. View at Publisher · View at Google Scholar
  71. R. Vita, D. Lapa, F. Trimarchi, and S. Benvenga, “Stress triggers the onset and the recurrences of hyperthyroidism in patients with Graves’ disease,” Endocrine, vol. 48, no. 1, pp. 254–263, 2015. View at Publisher · View at Google Scholar · View at Scopus
  72. L. Chiovato, M. Marino, G. Perugi et al., “Chronic recurrent stress due to panic disorder does not precipitate Graves’ disease,” Journal of Endocrinological Investigation, vol. 21, no. 11, pp. 758–764, 1998. View at Publisher · View at Google Scholar
  73. G. Effraimidis, J. G. Tijssen, J. F. Brosschot, and W. M. Wiersinga, “Involvement of stress in the pathogenesis of autoimmune thyroid disease: a prospective study,” Psychoneuroendocrinology, vol. 37, no. 8, pp. 1191–1198, 2012. View at Publisher · View at Google Scholar · View at Scopus
  74. K. Kamoi, M. Tanaka, T. Ikarashi, and M. Miyakoshi, “Effect of the 2004 mid Niigata prefecture earthquake on patients with endocrine disorders,” Endocrine Journal, vol. 53, no. 4, pp. 511–521, 2006. View at Publisher · View at Google Scholar · View at Scopus
  75. A. Fukao, J. Takamatsu, Y. Murakami et al., “The relationship of psychological factors to the prognosis of hyperthyroidism in antithyroid drug-treated patients with Graves’ disease,” Clinical Endocrinology, vol. 58, no. 5, pp. 550–555, 2003. View at Publisher · View at Google Scholar · View at Scopus
  76. A. Fukao, J. Takamatsu, S. Kubota, A. Miyauchi, and T. Hanafusa, “The thyroid function of Graves’ disease patients is aggravated by depressive personality during antithyroid drug treatment,” BioPsychoSocial Medicine, vol. 5, no. 1, p. 9, 2011. View at Google Scholar
  77. K. Yoshiuchi, H. Kumano, S. Nomura et al., “Psychosocial factors influencing the short-term outcome of antithyroid drug therapy in Graves’ disease,” Psychosomatic Medicine, vol. 60, no. 5, pp. 592–596, 1998. View at Publisher · View at Google Scholar
  78. F. Azizi, “Environmental iodine intake affects the response to methimazole in patients with diffuse toxic goiter,” The Journal of Clinical Endocrinology and Metabolism, vol. 61, no. 2, pp. 374–377, 1985. View at Publisher · View at Google Scholar
  79. T. Nakashima, A. Taurog, and G. Riesco, “Mechanism of action of thioureylene antithyroid drugs: factors affecting intrathyroidal metabolism of propylthiouracil and methimazole in rats,” Endocrinology, vol. 103, no. 6, pp. 2187–2197, 1978. View at Publisher · View at Google Scholar
  80. W. D. Alexander, R. M. Harden, D. A. Koutras, and E. Wayne, “Influence of iodine intake after treatment with antithyroid drugs,” Lancet, vol. 2, no. 7418, pp. 866–868, 1965. View at Google Scholar
  81. E. Roti, E. Gardini, R. Minelli et al., “Effects of chronic iodine administration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves’ hyperthyroidism,” The Journal of Clinical Endocrinology and Metabolism, vol. 76, no. 4, pp. 928–932, 1993. View at Publisher · View at Google Scholar
  82. P. W. Wang, R. T. Liu, S. C. Tung et al., “Outcome of Graves’ disease after antithyroid drug treatment in Taiwan,” Journal of the Formosan Medical Association, vol. 97, no. 9, pp. 619–625, 1998. View at Google Scholar
  83. N. B. Tutuncu, T. Tutuncu, A. Ozgen, and T. Erbas, “Long-term outcome of Graves’ disease patients treated in a region with iodine deficiency: relapse rate increases in years with thionamides,” Journal of the National Medical Association, vol. 98, no. 6, pp. 926–930, 2006. View at Google Scholar
  84. S. M. Park, Y. Y. Cho, J. Y. Joung, S. Y. Sohn, S. W. Kim, and J. H. Chung, “Excessive iodine intake does not increase the recurrence rate of Graves’ disease after withdrawal of the antithyroid drug in an iodine-replete area,” European Thyroid Journal, vol. 4, no. 1, pp. 36–42, 2015. View at Publisher · View at Google Scholar
  85. B. L. Solomon, J. E. Evaul, K. D. Burman, and L. Wartofsky, “Remission rates with antithyroid drug therapy: continuing influence of iodine intake?” Annals of Internal Medicine, vol. 107, no. 4, pp. 510–512, 1987. View at Publisher · View at Google Scholar
  86. F. Baeke, T. Takiishi, H. Korf, C. Gysemans, and C. Mathieu, “Vitamin D: modulator of the immune system,” Current Opinion in Pharmacology, vol. 10, no. 4, pp. 482–496, 2010. View at Publisher · View at Google Scholar · View at Scopus
  87. A. Misharin, M. Hewison, C. R. Chen et al., “Vitamin D deficiency modulates Graves’ hyperthyroidism induced in BALB/c mice by thyrotropin receptor immunization,” Endocrinology, vol. 150, no. 2, pp. 1051–1060, 2009. View at Publisher · View at Google Scholar · View at Scopus
  88. E. Borgogni, E. Sarchielli, M. Sottili et al., “Elocalcitol inhibits inflammatory responses in human thyroid cells and T cells,” Endocrinology, vol. 149, no. 7, pp. 3626–3634, 2008. View at Publisher · View at Google Scholar · View at Scopus
  89. D. Shin, S. Hwang, D. Kim, K. Kim, and E. Lee, “Baseline vitamin D level could be a short-term prognostic marker in patients with Graves’ disease,” in Thyroid, D. Shin, S. Hwang, D. Kim, and E. Lee, Eds., vol. 21, p. A48, Department of Internal Medicine, Yonsei University, College of Medicine, Seoul, South Korea, 2011. View at Publisher · View at Google Scholar
  90. T. Yasuda, Y. Okamoto, N. Hamada et al., “Serum vitamin D levels are decreased and associated with thyroid volume in female patients with newly onset Graves’ disease,” Endocrine, vol. 42, no. 3, pp. 739–741, 2012. View at Publisher · View at Google Scholar · View at Scopus
  91. J. Reglinski, W. E. Smith, R. Wilson, D. J. Halls, J. H. McKillop, and J. A. Thomson, “Selenium in Graves’ disease,” Clinica Chimica Acta, vol. 211, no. 3, pp. 189–190, 1992. View at Publisher · View at Google Scholar · View at Scopus
  92. I. Bulow Pedersen, N. Knudsen, A. Carle et al., “Serum selenium is low in newly diagnosed Graves’ disease: a population-based study,” Clinical Endocrinology, vol. 79, no. 4, pp. 584–590, 2013. View at Publisher · View at Google Scholar · View at Scopus
  93. L. Wang, B. Wang, S. R. Chen et al., “Effect of selenium supplementation on recurrent hyperthyroidism caused by Graves’ disease: a prospective pilot study,” Hormone and Metabolic Research, vol. 48, no. 9, pp. 559–564, 2016. View at Publisher · View at Google Scholar · View at Scopus
  94. J. J. Khong, R. F. Goldstein, K. M. Sanders et al., “Serum selenium status in Graves’ disease with and without orbitopathy: a case-control study,” Clinical Endocrinology, vol. 80, no. 6, pp. 905–910, 2014. View at Publisher · View at Google Scholar · View at Scopus
  95. L. H. Duntas, “The evolving role of selenium in the treatment of Graves’ disease and ophthalmopathy,” Journal of Thyroid Research, vol. 2012, Article ID 736161, 2012. View at Google Scholar
  96. T. Wertenbruch, H. S. Willenberg, C. Sagert et al., “Serum selenium levels in patients with remission and relapse of Graves’ disease,” Medicinal Chemistry, vol. 3, no. 3, pp. 281–284, 2007. View at Publisher · View at Google Scholar · View at Scopus
  97. J. Calissendorff, E. Mikulski, E. H. Larsen, and M. Moller, “A prospective investigation of Graves’ disease and selenium: thyroid hormones, auto-antibodies and self-rated symptoms,” European Thyroid Journal, vol. 4, no. 2, pp. 93–98, 2015. View at Publisher · View at Google Scholar
  98. A. P. Weetman, “Graves’ disease,” The New England Journal of Medicine, vol. 343, no. 17, pp. 1236–1248, 2000. View at Publisher · View at Google Scholar · View at Scopus
  99. X. Liu, W. Qiang, L. Liu et al., “A second course of antithyroid drug therapy for recurrent Graves’ disease: an experience in endocrine practice,” European Journal of Endocrinology, vol. 172, no. 3, pp. 321–326, 2015. View at Publisher · View at Google Scholar · View at Scopus
  100. D. Villagelin, J. H. Romaldini, R. B. Santos, A. B. Milkos, and L. S. Ward, “Outcomes in relapsed Graves’ disease patients following radioiodine or prolonged low dose of methimazole treatment,” Thyroid, vol. 25, no. 12, pp. 1282–1290, 2015. View at Publisher · View at Google Scholar · View at Scopus